Irsogladine/lafutidine

伊索拉定/拉呋替丁

Report date: 2022/07/04 19:38:02

Base Information

Drug NameIrsogladine/lafutidine
Drug Alias Name拉呋替丁/伊索拉定Lafutidine+Irsogladine MaleateLafutidine/Irsogladine Maleate拉呋替丁/马来酸伊索拉定Lafutidine/Irsogladine +[11] 
ClassificationSmall molecules
Mechanisms of ActionHistamine H2 receptor antagonists3',5'-cyclic phosphodiesterase inhibitors
Targets3',5'-cyclic phosphodiesteraseHistamine H2 receptor
Therapy Area/IndicationsStomach UlcerPeptic Ulcer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes Irsogladine MaleateLafutidine
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBoryung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoryung Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsStomach UlcerPeptic Ulcer

Other Information

ATC CodeN/A
Related LinksN/A